Rimiducid
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Rimiducid
- Molecular weight
- 1,411.65
- Structure (SMILES)
- CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1
- 2 piperidinecarboxylic acid 1 2s 1 oxo 2 3 4 5 trimethoxyphenyl butyl 2 2 1 2 ethanediylbis imino 2 oxo 2 1 ethanediyl oxy 3 1 phenylene 1r 3 3 4 dimethoxyphenyl propylidene ester 2s 2 s
- 2-PIPERIDINECARBOXYLIC ACID, 1-((2S)-1-OXO-2-(3,4,5-TRIMETHOXYPHENYL)BUTYL)-, 2,2'-(1,2-ETHANEDIYLBIS(IMINO(2-OXO-2,1-ETHANEDIYL)OXY-3,1-PHENYLENE((1R)-3-(3,4-DIMETHOXYPHENYL)PROPYLIDENE))) ESTER, (2S,2'S)-
- ap 1903
- AP-1903
- ap1903
- AP1903
- rimiducid
- Rimiducid
- Rimiducid (AP1903)
- rimiducid [INN]
- RIMIDUCID [USAN]
- Rimiducid [WHO-DD]
- rimiducid inn
- rimiducid usan
- rimiducid who dd
- CAS registry numbers
- 195514-63-7
- ChEMBL ID
- CHEMBL269259
- InChIKey
- GQLCLPLEEOUJQC-ZTQDTCGGSA-N
- PubChem compound IDs
- 16135625
- FDA ingredient codes (UNII)
- H564L1W5J2
- First in class
- No
- Orphan designation
- No
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Multiple Myeloma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition
- Hematologic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0044881
- Subject identifier
- D019337
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001378
- Condition identifier
- MONDO_0002334
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002571
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004952
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005036
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005059
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005062
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005072
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005556
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005570
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006451
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006456
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006486
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009807
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 1
And 7 more, listed on the interactive page.
- NCT00868595
- NCT01823978
- NCT02744287
- NCT01744223
- NCT02743611
- NCT03016377
- NCT03056339
- NCT02477878
- NCT03459170
- NCT02487459
- NCT02792114
- NCT03288493
- NCT03958656
- NCT04960579
- NCT06066424
- Calculated partition coefficient (XLogP)
- 11.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 102
- Molecular formula
- C78H98N4O20
- Monoisotopic mass
- 1410.67744153
- Natural product
- No
- Recorded assays
- 17
- Active assays
- 4
- Confirmatory
- Screening
Related records
Trials (39)
- A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
- A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
- Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
- Administration of Donor T Cells With the Caspase-9 Suicide Gene
- Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
- BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study
- Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
- Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
- Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
- Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
- Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
- MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
- P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
- P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
- P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
- P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
- P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
- Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
- Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
- Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers
In development for (12)
- Acute lymphoblastic leukemia Phase 1
- Acute myeloid leukemia Phase 1
- B-cell chronic lymphocytic leukemia Phase 1
- Breast cancer Phase 1
- Cancer Phase 1
- Hematopoietic and lymphoid cell neoplasm Phase 1
- Lymphoma Phase 1
- Metastatic prostate carcinoma Phase 1
- Myelodysplastic syndrome Phase 1
- Neoplasm Phase 1
- Plasma cell myeloma Phase 1
- Prostate cancer Phase 1